Search

Background Idiopathic inflammatory myopathy (IIM) is a group of connective tissue diseases characterized by muscle inflammation and muscle weakness, lung involvement is an important factor affecting the prognosis of patients. IIM can be classified into different clinical subtypes based on myositis-specific antibodies (MSAs), there are significant differences in clinical manifestations, organ involvement, prognosis and the risk of interstitial lung disease among different clinical subtypes. Objective To explore the characteristics of IIM and its different clinical subtypes, the risk factors for the development of interstitial lung disease. Methods The clinical data of patients hospitalizedin department of rheumatology and immunology of the First Affiliated Hospital of Kunming Medical University and diagnosed with IIM from April 2018 to February 2021 were collected. The included patients were divided into four clinical subtypes based on MSAs, including anti-MDA5-positive dermatomyositis (DM), anti-MDA5-negative DM, immune-mediated necrotizing myositis (IMNM) and anti-synthetase syndrome (ASS) subtypes. The general data, clinical manifestations, laboratory examination results were compared among different clinical subtypes. Multivariate Logistic regression model was established to explore the risk factors for ILD in patients with IIM. Results The 150 patients with IIM were divided into 4 clinical subtypes, including 30 patients with anti-MDA5-positive DM subtype (20.0%), 58 patients with anti-MDA5-negative DM subtype (38.7%), 14 patients with IMNM subtype (9.3%), and 48 patients with ASS subtype (32.0%). There were significant differences in the incidence of muscle weakness, myalgia, ILD, heliotrope rash, shawl sign, Gottron papules or Gottron sign, arthralgia, periungual red spot and dysphagia among the four clinical subtypes (P403.2 μg/L, IgG>14.15 g/L, LDH>359.5 U/L were all risk factors for ILD in IIM (P

A noninvasive strategy for in situ diagnosis and precise treatment of bacterial biofilm infections is highly anticipated but still a great challenge. Currently, no in vivo biofilm-targeted theranostic agent is available. Herein, we fabricated intelligent theranostic alginate lyase (Aly)-NaNdF 4 nanohybrids with a 220 nm sunflower-like structure (NaNdF 4 @DMS-Aly) through an enrichment-encapsulating strategy, which exhibited excellent photothermal conversion efficiency and the second near-infrared (NIR-II) luminescence. Benefiting from the site-specific targeting and biofilm-responsive Aly release from NaNdF 4 @DMS-Aly, we not only enabled noninvasive diagnosis but also realized Aly-photothermal synergistic therapy and real-time evaluation of therapeutic effect in mice models with Pseudomonas aeruginosa biofilm-induced pulmonary infection. Furthermore, such nanobiohybrids with a sheddable siliceous shell are capable of delaying the NaNdF 4 dissolution and biodegradation upon accomplishing the therapy, which is highly beneficial for the biosafety of theranostic agents.

Here, we report a novel strategy for the direct construction of polycyclic fused ortho -quinone scaffolds through palladium(II)-catalyzed tandem γ-C(sp 2 )-H arylation and cyclization of arylglyoxals with aryl iodides. This transformation features unique tandem transient directing of γ-C(sp 2 )-H arylation and cyclization reaction mode, broad substrate scope, especially for the aromatic substrates containing oxygen and sulfur atoms, and avoiding the common issue of aromatization due to the construction of the hexatomic ring.